The present study aims to identify patterns for use of medication given pro re nata (PRN or "on an as needed [preordered] basis") or statim (STAT [a new order] or "at once, immediately") and their efficacy in controlling aggressive behavior in the mental health (MH) services environment. PRN and STAT medication data were combined and referred to as PRN throughout this article, as the data were not collected in a manner required to differentiate between PRN and STAT medication administration. Analyzed data were extracted from the clinical records of a sample of children and youth admitted for the first time to a tertiary MH center. MH Program patients (characterized by at least one Axis I psychiatric diagnosis [Axis I group]) were compared to Dual Diagnosis Program patients (characterized by an Axis I diagnosis in addition to an Axis II diagnosis of mental retardation [Axis II group]). Age, gender, Program (Axis I or II group), and the length of stay for treatment produced significant differences in the use of PRNs between the two groups. Further, the study investigated the precipitating factors leading to use of PRNs, in conjunction with the level of supervision and the de-escalation techniques used to avoid the use of PRNs. Axis I patients were more likely to endanger others, whereas Axis II patients were more likely to endanger themselves. Both groups of patients demonstrated a need for an increased level of supervision prior to the crisis. Olanzapine, chlorpromazine, and lorazepam were effective in calming patients and preventing further aggressive outbursts.

Download full-text PDF

Source
http://dx.doi.org/10.1089/cap.2010.0010DOI Listing

Publication Analysis

Top Keywords

pro nata
8
mental health
8
prn stat
8
stat medication
8
program patients
8
patients characterized
8
characterized axis
8
[axis group]
8
axis diagnosis
8
level supervision
8

Similar Publications

Background/objectives: Neovascular age-related macular degeneration (nAMD) is a retinal disorder leading to irreversible central vision loss. The pro-re-nata (PRN) treatment for nAMD involves frequent intravitreal injections of anti-VEGF medications, placing a burden on patients and healthcare systems. Predicting injections needs at each monitoring session could optimize treatment outcomes and reduce unnecessary interventions.

View Article and Find Full Text PDF

Purpose: To evaluate the anatomic and visual outcomes and safety profile of initial Indian eyes with neovascular age-related macular degeneration (nAMD) treated with intravitreal injection (IVI) of brolucizumab.

Methods: This retrospective multicentric, real-world study enrolled consecutive eyes with nAMD that were treated with IVI brolucizumab after it was launched in India in October 2020. Data collected for each eye included best-corrected visual acuity (BCVA), central subfield thickness (CSFT), subretinal fluid (SRF), and intraretinal fluid (IRF) status at 6, 12, and 24 months follow-up.

View Article and Find Full Text PDF
Article Synopsis
  • The study investigates the quality of referrals to community palliative care teams, focusing on patient criteria for at-home care and the challenges in transitioning from hospital care to specialized palliative support.
  • Researchers analyzed patient records from 2023, noting an average patient age of 80.7 years, with common diagnoses including cancer and organ failure, and found improvements in psychological and social support after starting palliative care.
  • The findings suggest that while many patients can be supported effectively at home, there are significant issues with recognizing referral criteria and delays in transitioning care from hospitals.
View Article and Find Full Text PDF

Purpose: The natural course of the visual acuity in eyes with myopic macular neovascularization (myopic MNV) is poor. Intravitreal injections of anti-vascular endothelial growth factor (VEGF) agents have demonstrated safety and efficacy in the short-term for managing myopic MNV. The purpose of this study was to determine the 4-year outcomes of intravitreal aflibercept (IVA) injections.

View Article and Find Full Text PDF
Article Synopsis
  • The study aimed to explore changes in choroidal blood flow (CBF) and choroidal thickness (CT) in eyes with non-ischemic branch retinal vein occlusion (BRVO) after treatment with intravitreal aflibercept injections (IVA).
  • Conducted on 20 treatment-naive patients, measurements were taken before and after treatment using laser speckle flowgraphy and optical coherence tomography, revealing significant reductions in CBF and CT at specific times post-treatment.
  • The findings suggest that aflibercept injections led to decreases in both CBF and CT, which may correlate with improvements in macular edema among the studied BRVO eyes.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!